RAPT Therapeutics (RAPT) Total Current Liabilities: 2020-2024
Historic Total Current Liabilities for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to $10.4 million.
- Therapeutics' Total Current Liabilities fell 52.57% to $10.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.4 million, marking a year-over-year decrease of 52.57%. This contributed to the annual value of $21.8 million for FY2023, which is 53.52% up from last year.
- Latest data reveals that Therapeutics reported Total Current Liabilities of $10.4 million as of Q3 2024, which was down 29.99% from $14.8 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Total Current Liabilities registered a high of $21.8 million during Q3 2023, and its lowest value of $9.6 million during Q4 2021.
- Its 3-year average for Total Current Liabilities is $16.4 million, with a median of $14.8 million in 2024.
- Per our database at Business Quant, Therapeutics' Total Current Liabilities spiked by 74.82% in 2023 and then tumbled by 52.57% in 2024.
- Therapeutics' Total Current Liabilities (Quarterly) stood at $11.7 million in 2020, then fell by 18.28% to $9.6 million in 2021, then surged by 48.24% to $14.2 million in 2022, then soared by 53.52% to $21.8 million in 2023, then plummeted by 52.57% to $10.4 million in 2024.
- Its last three reported values are $10.4 million in Q3 2024, $14.8 million for Q2 2024, and $21.2 million during Q1 2024.